Status:
COMPLETED
Argus II/ORCAM Device Study
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Second Sight Medical Products
Conditions:
Retinitis Pigmentosa
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is being done to determine if wearable text-to-speech (TTS) and visual pattern recognition (VPR) technology can be used to extend the capabilities of the Argus II to allow patients to read ...
Detailed Description
The Orcam device will be mounted onto the Argus II eyeglasses. The subject will be asked to use the Orcam device with and without the Argus II. After a half-day interactive training session with the O...
Eligibility Criteria
Inclusion
- Diagnosis of advanced retinitis pigmentosa
- Subjects must have an Argus II device implanted to be eligible for this study
- Subjects must be familiar with using their Argus II device
Exclusion
- \- No Argus II implant
Key Trial Info
Start Date :
August 31 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2020
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03248388
Start Date
August 31 2017
End Date
October 15 2020
Last Update
January 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905